This Special Issue (SI) has collected the most recent publications on the mechanisms that macrophages use to regulate homeostasis and their involvement in the pathogenesis of various non-infectious diseases.

Among others, atherosclerosis can be considered as an inevitable disease, strongly associated with age, and significantly contributing to the death rate of all countries.

The pathological thickening of the walls of large arteries can be seen as a macroscopic manifestation of this disease, and when we increase the scale we can see that macrophages contribute significantly by secreting pro-inflammatory cytokines leading to chronic inflammation, participating in the formation of atherosclerotic lesions in the form of foam cells [1,2]. However, when it comes to the identification of the origins of atherosclerosis, there is still no unity among researchers.

One promising hypothesis combining different observations related to atherosclerosis pathology is that mutations of mitochondrial DNA could modulate the inflammatory response of macrophages to different pro-inflammatory stimuli, leading to chronic inflammation and further development of the disease [3,4]. As a part of the innate immune system, macrophages are capable of recognizing pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), and can trigger immune response. Dysfunctional mitochondria (for example, due to mutations of mitochondrial DNA) contribute to DAMPs formation. Atherogenic low-density lipoproteins (LDL), including desialylated and oxidized ones [2,5], can also serve as a unique trigger of inflammation independent of DAMPs and PAMPs. It should be noted that the principles described in this hypothesis can also be applied to other diseases related to chronic inflammation. This hypothesis is shown in Figure 1.

We shall briefly summarize below articles and reviews published in this Special Issue.

It was found that infection of anti-inflammatory M2-macrophages with rubella virus was accompanied by a reduction in CD14 expression and the interferon β response [6].

Specific gene profiles were identified in heart macrophages in cases of early compensated hypertrophy (genes related to lipid metabolism and genes of Na+ or K+ channels) versus late dilated remodeling related to heart failure [7].

The influence of heat-killed Candida albicans cells on macrophages was studied with the conclusion that these cells can induce foam cell formation, MMP-9 expression, and inflammatory response via upregulated FABP4. Thus, FABP4 could be considered as a new drug target to treat atherosclerosis induced by C. albicans [8].

The potential connection of high levels of lipid peroxidation with elevated ferritin was investigated in case of adult-onset Still’s disease [9].
Macrophages without mutations of mitochondrial DNA 

- stimulation of inflammatory response, DAMPs, PAMPs, atherogenic LDL 

- tolerance, limited secretion of pro-inflammatory cytokines 

- resolved inflammation 

Macrophages with mutations of mitochondrial DNA 

- intolerance, continuous secretion of pro-inflammatory cytokines 

- chronic inflammation 

**Figure 1.** The hypothesis of the induction of chronic inflammation due to the presence of mutations of mitochondrial DNA in macrophages. Macrophages can recognize damage-associated molecular patterns (DAMPs), pathogen-associated molecular patterns (PAMPs), and atherogenic low-density lipoproteins (LDL), turn on a pro-inflammatory reaction, and secrete pro-inflammatory cytokines. In normal cases, a tolerance develops, and the macrophage stops releasing cytokines. However, in the presence of mitochondrial mutations, tolerance formation may be impaired, which could lead to continuous secretion of inflammatory cytokines and chronic inflammation development [3,4].

The influence of lobeglitazone on lipopolysaccharide-treated bone-marrow-derived macrophages was studied, with the conclusion that it has anti-inflammatory activity due to the suppression of expression of pro-inflammatory genes and reduced NO production [10].

Using a mouse model, a line of human macrophages, and an agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor, a reduction in foam cell formation was shown upon the activation of the GIP receptor, which correlated with a reduction in expression of CD36 and CDK5 [13].

Macrophages were purified from different regions of lungs based on density of cells, with the finding that high-density and low-density macrophages had differences not only in density but also in the expression of certain gene markers and inflammatory response upon the addition of lipopolysaccharide [14].

Co-incubation of mesenchymal stem cells with M2 macrophages in a 3D environment containing polyethylene particles with lipopolysaccharides resulted in an elevated production of markers of osteogenesis. This suggests a potential role of the immune response in modulation of bone reparation [15].

It was found that incubation of macrophages with carnosine led to a reduction in oxidative stress caused by Aβ1-42 oligomers and thus protected cells from death and apoptosis. This points in the direction of potential therapeutic application of this peptide in the treatment of Alzheimer’s disease [16].

There was increased production of interleukin-8 and prostaglandin E2 in THP-1-derived macrophages after palmitate treatment, and insulin enhanced these effects, suggesting the role of palmitate in the progression of inflammation in adipose tissues [17].
The pathological role of macrophages in development and progression of erectile dysfunction (ED), and Peyronie’s disease as an example of ED, was reviewed and discussed, including current therapeutic approaches [18].

The complex subject of training and tolerance of macrophages was discussed with special focus on the role of macrophages in the development of diseases in humans [19].

Questions related to metabolism of iron in macrophages, considering their role in degradation of red blood cells, were carefully reviewed [20].

The influence of activation of microglia on pathological development of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and epilepsy was discussed, with mention of potential therapy approaches [21].

Current methods related to the identification of macrophages in situ were systematized and discussed, including in situ hybridization, immunolabeling and other approaches [22].

The interaction between macrophages, mesenchymal stem cells and fibroblasts in the tumor microenvironment was analyzed, with a focus on cell–cell interaction and secreted mediators, in order to find explanations for pro/anti-tumor phenotypes of macrophages and their response to treatment with oncolytic viruses [23].

The role of macrophages in foam cell formation in atherosclerosis, mechanisms involved in this process, as well as their potential as targets for anti-atherosclerotic therapy, were reviewed [24].

The effect of Roux-en-Y gastric bypass on different pathways involving energy homeostasis in leukocytes was studied, with the finding of increased levels of AMPK, autophagy/mitophagy markers, a reduction in ATF6 and CHOP (ER stress markers), and decreased mitochondrial membrane potential [25].

The influence of microbeam radiation therapy on accumulation of macrophages was studied in different tissues, and accumulation of macrophages in normal liver and lung tissue and lung carcinoma was found in comparison to in normal skin tissue [26].

We hope that the next SI will continue the traditions of high-quality publications established in this and previous SIs.

**Author Contributions:** Writing—original draft preparation, E.E.B., A.G., A.N.O.; writing—review and editing, E.E.B., A.G., A.N.O. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by the Russian Science Foundation, grant number 20-15-00264.

**Institutional Review Board Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Malekmohammad, K.; Bezsonov, E.E.; Rafieian-Kopaei, M. Role of Lipid Accumulation and Inflammation in Atherosclerosis: Focus on Molecular and Cellular Mechanisms. *Front. Cardiovasc. Med.* 2021, 8, 707529. [CrossRef] [PubMed]

2. Mushenkova, N.V.; Bezsonov, E.E.; Orekhova, V.A.; Popkova, T.V.; Starodubova, A.V.; Orekhov, A.N. Recognition of Oxidized Lipids by Macrophages and Its Role in Atherosclerosis Development. *Biomedicines* 2021, 9, 915. [CrossRef] [PubMed]

3. Bezsonov, E.E.; Gratchev, A.; Orekhov, A.N. Macrophages in Health and Non-Infectious Disease. *Biomedicines* 2021, 9, 460. [CrossRef] [PubMed]

4. Bezsonov, E.E.; Sobenin, I.A.; Orekhov, A.N. Immunopathology of Atherosclerosis and Related Diseases: Focus on Molecular Biology. *Int. J. Mol. Sci.* 2021, 22, 4080. [CrossRef]

5. Mezentsev, A.; Bezsonov, E.; Kashirskikh, D.; Baig, M.S.; Eid, A.H.; Orekhov, A. Proatherogenic Sialidases and Desialylated Lipoproteins: 35 Years of Research and Current State from Bench to Bedside. *Biomedicines* 2021, 9, 600. [CrossRef] [PubMed]

6. Schilling, E.; Pfeiffer, L.; Hauschildt, S.; Koehl, U.; Claus, C. CD14 Is Involved in the Interferon Response of Human Macrophages to Rubella Virus Infection. *Biomedicines* 2022, 10, 266. [CrossRef] [PubMed]

7. Nadaud, S.; Flamant, M.; Le Goff, W.; Balse, E.; Pavoine, C. Transcriptomic and Lipidomic Mapping of Macrophages in the Hub of Chronic Beta-Adrenergic-Stimulation Unravels Hypertrophy-, Proliferation-, and Lipid Metabolism-Related Genes as Novel Potential Markers of Early Hypertrophy or Heart Failure. *Biomedicines* 2022, 10, 221. [CrossRef]

8. Haider, M.; Al-Rashed, F.; Albaqumi, Z.; Alobaid, K.; Alqabandi, R.; Al-Mulla, F.; Ahmad, R. *Candida albicans* Induces Foaming and Inflammation in Macrophages through FABP4: Its Implication for Atherosclerosis. *Biomedicines* 2021, 9, 1567. [CrossRef]
9. Chen, P.-K.; Yeo, K.-J.; Huang, P.-H.; Chang, S.-H.; Chang, C.-K.; Lan, J.-L.; Chen, D.-Y. Increased Lipid Peroxidation May Be Linked to Ferritin Levels Elevation in Adult-Onset Still’s Disease. *Biomedicines* 2021, 9, 1508. [CrossRef]

10. Jeong, D.; Ko, W.-K.; Kim, S.-J.; Han, G.-H.; Lee, D.; Sheen, S.-H.; Sohn, S. Lobeglitazone Exerts Anti-Inflammatory Effect in Lipopolysaccharide-Induced Bone-Marrow Derived Macrophages. *Biomedicines* 2021, 9, 1432. [CrossRef] [PubMed]

11. Tsurutani, M.; Horie, H.; Ogawa, K. Cell Properties of Lung Tissue-Resident Macrophages Propagated by Co-Culture with Lung Fibroblastic Cells from C57BL/6 and BALB/c Mice. *Biomedicines* 2021, 9, 1241. [CrossRef] [PubMed]

12. Elchaninov, A.; Lokhonina, A.; Vishnyakova, P.; Soboleva, A.; Poltavets, A.; Artemova, D.; Makarov, A.; Glinkina, V.; Goldshtein, D.; Bolshakova, G.; et al. MARCO+ Macrophage Dynamics in Regenerating Liver after 70% Liver Resection in Mice. *Biomedicines* 2021, 9, 1129. [CrossRef] [PubMed]

13. Terasaki, M.; Yashima, H.; Mori, Y.; Saito, T.; Shiraga, Y.; Kawakami, R.; Ohara, M.; Fukui, T.; Hirano, T.; Yamada, Y.; et al. Glucose-Dependent Insulinotropic Polypeptide Suppresses Foam Cell Formation of Macrophages through Inhibition of the Cyclin-Dependent Kinase 5-CD36 Pathway. *Biomedicines* 2021, 9, 832. [CrossRef] [PubMed]

14. Balestrieri, B.; Granata, F.; Loffredo, S.; Petraroli, A.; Scalia, G.; Morabito, P.; Cardamone, C.; Varricchi, G.; Triggiani, M. Phenotypic and Functional Heterogeneity of Low-Density and High-Density Human Lung Macrophages. *Biomedicines* 2021, 9, 505. [CrossRef]

15. Gao, Q.; Rhee, C.; Maruyama, M.; Li, Z.; Shen, H.; Zhang, N.; Utsunomiya, T.; Huang, E.E.; Yao, Z.; Bunnell, B.A.; et al. The Effects of Macrophage Phenotype on Osteogenic Differentiation of MSCs in the Presence of Polyethylene Particles. *Biomedicines* 2021, 9, 477. [CrossRef]

16. Caruso, G.; Benatti, C.; Musso, N.; Fresta, C.G.; Fidilio, A.; Spampinato, G.; Brunello, N.; Bucolo, C.; Drago, F.; Lunte, S.M.; et al. Carnosine Protects Macrophages against the Toxicity of Aβ1-42 Oligomers by Decreasing Oxidative Stress. *Biomedicines* 2021, 9, 1658. [CrossRef] [PubMed]

17. Henkel, J.; Klauder, J.; Statz, M.; Wohlenberg, A.-S.; Kuipers, S.; Vahrenbrink, M.; Püschel, G.P. Enhanced Palmitate-Induced Interleukin-8 Formation in Human Macrophages by Insulin or Prostaglandin E2. *Biomedicines* 2021, 9, 449. [CrossRef]

18. Recalcati, S.; Cairo, G. Macrophages and Iron: A Special Relationship. *Biomedicines* 2021, 9, 1585. [CrossRef]

19. Nikovics, K.; Favier, A.-L. Macrophage Identification In Situ. *Biomedicines* 2021, 9, 1393. [CrossRef] [PubMed]

20. Di Somma, S.; Napolitano, F.; Portella, G.; Malititano, A.M. Cross Talk of Macrophages with Tumor Microenvironment Cells and Modulation of Macrophages in Cancer by Virotherapy. *Biomedicines* 2021, 9, 1309. [CrossRef] [PubMed]

21. Poznyak, A.V.; Nikiforov, N.G.; Starodubova, A.V.; Popkova, T.V.; Orekhov, A.N. Macrophages and Foam Cells: Brief Overview of Their Role, Linkage, and Targeting Potential in Atherosclerosis. *Biomedicines* 2021, 9, 1221. [CrossRef]

22. Abad-Jiménez, Z.; López-Domènech, S.; García-Gargallo, C.; Vezza, T.; Gómez-Abril, S.A.; Morillas, C.; Díaz-Pozo, P.; Falcón, R.; Bañuls, C.; Víctor, V.M.; et al. Roux-en-Y Gastric Bypass Modulates AMPK, Autophagy and Inflammatory Response in Leukocytes of Obese Patients. *Biomedicines* 2022, 10, 430. [CrossRef]

23. Trappetti, V.; Fazzari, J.; Fernandez-Palomino, C.; Smyth, L.; Potez, M.; Shintani, N.; de Breuyn Dietler, B.; Martin, O.A.; Djonov, V. Targeted Accumulation of Macrophages Induced by Microbeam Irradiation in a Tissue-Dependent Manner. *Biomedicines* 2022, 10, 735. [CrossRef]